PubMed:6419786 / 1608-1749
Annnotations
GlyCosmos15-CL
{"project":"GlyCosmos15-CL","denotations":[{"id":"T14","span":{"begin":77,"end":79},"obj":"Cell"}],"attributes":[{"id":"A14","pred":"cl_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CL:0004120"}],"text":"Suppression of endogenous TSH by thyroxine treatment depresses prostaglandin I2 contents and augments prostaglandin E2 and F2 alpha contents."}
GlyCosmos15-Sentences
{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T10","span":{"begin":0,"end":141},"obj":"Sentence"}],"text":"Suppression of endogenous TSH by thyroxine treatment depresses prostaglandin I2 contents and augments prostaglandin E2 and F2 alpha contents."}
CL-cell
{"project":"CL-cell","denotations":[{"id":"T14","span":{"begin":77,"end":79},"obj":"Cell"}],"attributes":[{"id":"A14","pred":"cl_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CL:0004120"}],"text":"Suppression of endogenous TSH by thyroxine treatment depresses prostaglandin I2 contents and augments prostaglandin E2 and F2 alpha contents."}